Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Jonathan Tyler
Biological weapons, colloquially known as bioweapons, represent a category of weaponry that exploits living organisms or their byproducts to inflict harm upon humans, animals, or plants. This article offers a comprehensive exploration of the multifaceted world of biological weapons, encompassing their historical roots, evolution, and contemporary implications. The historical narrative of biological weapons is one fraught with episodes of their use in warfare, espionage, and acts of terror. From the hurling of contaminated carcasses into enemy territories in ancient times to the covert and sinister experiments conducted during the tumultuous 20th century, the timeline of bioweaponry is rife with ethical, humanitarian, and security concerns. The establishment of the Biological Weapons Convention (BWC) in 1972 marked a significant milestone in international efforts to curtail the production and use of biological weapons. However, despite these endeavors, contemporary concerns loom large. The ongoing threat of bioterrorism and the emergence of non-state actors with potential access to these perilous tools underscore the need for continued vigilance. This article delves into the potential consequences of biological weapons use, emphasizing the rapid and devastating spread of pathogens, protracted incubation periods, and the challenges associated with attribution and accountability. Moreover, it addresses the contemporary concerns stemming from the accessibility of bioweapon technology to individuals or groups with malicious intent, facilitated by the dual-use nature of biotechnology and genetic engineering.